<strong>Purpose:</strong> We evaluated the findings from 18F-DCFPyL PSMA PET-CTs performed on patients presenting biochemical recurrence (BCR) of prostate cancer (PCa) and assessed its impact on staging. M...<strong>Purpose:</strong> We evaluated the findings from 18F-DCFPyL PSMA PET-CTs performed on patients presenting biochemical recurrence (BCR) of prostate cancer (PCa) and assessed its impact on staging. Methods and materials: This was a multicenter retrospective analysis of patients with PCa and BCR who underwent 18F-DCFPyL PSMA PET-CT in 2020. The patients were stratified into two groups: BCR after prostatectomy (PSA ≥ 0.2 ng/mL) or BCR after radiotherapy (PSA ≥ 2 ng/mL + nadir). We analyzed the lesions according to number and location. The Shapiro-Wilk test was used to estimate the distribution of the variables. We calculated representative statistics for the quantitative variables including the mean, standard deviation, median, and interquartile range. The association between qualitative variables was examined using Chi-squared tests. <strong>Results:</strong> 40 patients with BCR were analyzed;67.5% presented disease progression, predominantly distant recurrence (42.5%), which was found exclusively in bone;55% presented ≤5 lesions and of these, 68.2% only presented 1 lesion. There was a change in staging in 66.7% of the cases;17.7% received ablative treatment with stereotactic radiotherapy (SABR). <strong>Conclusions:</strong> 18F-DCFPyL PSMA PET-CT represents a new way to manage patients with BCR that, in this study, resulted in a change in staging in 66.7% of cases and early identification of oligometastatic progressions in the subgroup of patients with PSA < 0.5 ng/mL.展开更多
2021-05-27,美国食品药品监督管理局(FDA)正式批准美国Lantheus公司的Piflufolastat F 18注射液(18F标记的诊断显像剂,商品名:PYLARIFY■)用于前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病变的正电子发射型计算机断层显像(PET),以便更...2021-05-27,美国食品药品监督管理局(FDA)正式批准美国Lantheus公司的Piflufolastat F 18注射液(18F标记的诊断显像剂,商品名:PYLARIFY■)用于前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病变的正电子发射型计算机断层显像(PET),以便更加准确地识别前列腺癌的疑似转移或复发。Piflufolastat F 18被FDA批准用于2种适应证:第1个是对首诊疑似前列腺癌患者的初步分期;第2个是鉴别前列腺癌生化复发患者病灶的再分期。展开更多
文摘<strong>Purpose:</strong> We evaluated the findings from 18F-DCFPyL PSMA PET-CTs performed on patients presenting biochemical recurrence (BCR) of prostate cancer (PCa) and assessed its impact on staging. Methods and materials: This was a multicenter retrospective analysis of patients with PCa and BCR who underwent 18F-DCFPyL PSMA PET-CT in 2020. The patients were stratified into two groups: BCR after prostatectomy (PSA ≥ 0.2 ng/mL) or BCR after radiotherapy (PSA ≥ 2 ng/mL + nadir). We analyzed the lesions according to number and location. The Shapiro-Wilk test was used to estimate the distribution of the variables. We calculated representative statistics for the quantitative variables including the mean, standard deviation, median, and interquartile range. The association between qualitative variables was examined using Chi-squared tests. <strong>Results:</strong> 40 patients with BCR were analyzed;67.5% presented disease progression, predominantly distant recurrence (42.5%), which was found exclusively in bone;55% presented ≤5 lesions and of these, 68.2% only presented 1 lesion. There was a change in staging in 66.7% of the cases;17.7% received ablative treatment with stereotactic radiotherapy (SABR). <strong>Conclusions:</strong> 18F-DCFPyL PSMA PET-CT represents a new way to manage patients with BCR that, in this study, resulted in a change in staging in 66.7% of cases and early identification of oligometastatic progressions in the subgroup of patients with PSA < 0.5 ng/mL.
文摘2021-05-27,美国食品药品监督管理局(FDA)正式批准美国Lantheus公司的Piflufolastat F 18注射液(18F标记的诊断显像剂,商品名:PYLARIFY■)用于前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病变的正电子发射型计算机断层显像(PET),以便更加准确地识别前列腺癌的疑似转移或复发。Piflufolastat F 18被FDA批准用于2种适应证:第1个是对首诊疑似前列腺癌患者的初步分期;第2个是鉴别前列腺癌生化复发患者病灶的再分期。
